drugset
drugset / Trial / NCT05349214

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214 ↗

Phase 3 Active not recruiting 506 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjogren's syndrome (NEPTUNUS-2)

Timeline

Start
2022-08-04
Primary completion
2025-05-13
Completion
2027-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Ianalumab Monoclonal antibody — Subcutaneous

Indications

Sjogren syndrome